Ophthotech Corp Sets New 52-Week High at $43.19 (OPHT)
Shares of Ophthotech Corp (NASDAQ:OPHT) reached a new 52-week high on Wednesday , Analyst Ratings News reports. The company traded as high as $43.19 and last traded at $42.86, with a volume of 440,645 shares trading hands. The stock had previously closed at $41.75.
A number of analysts have recently weighed in on OPHT shares. Analysts at Morgan Stanley raised their price target on shares of Ophthotech Corp from $79.00 to $99.00 in a research note on Tuesday, May 20th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Ophthotech Corp from $40.00 to $51.00 in a research note on Tuesday, May 20th. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Ophthotech Corp from $55.00 to $58.00 in a research note on Tuesday, May 20th. They now have a “buy” rating on the stock.
The stock’s 50-day moving average is $34.41 and its 200-day moving average is $32.73. The company’s market cap is $1.442 billion.
Ophthotech Corp (NASDAQ:OPHT) last released its earnings data on Tuesday, May 13th. The company reported ($0.64) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.67) by $0.03. Analysts expect that Ophthotech Corp will post $-2.11 EPS for the current fiscal year.
In other Ophthotech Corp news, major shareholder Svlsf Iv, Llc unloaded 931,869 shares of the company’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $40.99, for a total transaction of $38,197,310.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.